• The Company
    • Who we are
    • Partner Portal
  • Meet the Partners
  • Our Approach
  • Portfolio
    • Current Portfolio
    • Historic Portfolio
  • News
  • Contact Us
The Vertical Group
Investing for Innovation

TetraLogic Announces Licensing and Research Collaboration With Walter and Eliza Hall Institute of Medical Research

1/21/2014

 
Via TetraLogic:
MALVERN, Pa., Jan. 21, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has entered into a research collaboration with the Walter and Eliza Hall Institute of Medical Research to examine TetraLogic's SMAC-Mimetic birinapant in viral infections. Preclinical studies performed at the WEHI have indicated that SMAC-Mimetics decrease the viral burden in mice with human Hepatitis B Virus (HBV) by inducing apoptosis of virally infected hepatocytes while sparing the non-infected cells.

TetraLogic has entered into a license agreement with WEHI for worldwide exclusive rights to a patent application filed by the institute relating to a method of treating intracellular infections involving the administration of an Inhibitor of Apoptosis (IAP) antagonist.

"Our work with TetraLogic, if successful, will provide a truly novel approach," said Professor Douglas Hilton, Director, WEHI. "This is further evidence of our commitment to perform research that has a direct impact on the lives of patients."

"We are very excited about this collaboration and look forward to further progress in the research program with WEHI," said Mr. Kevin Buchi, CEO of TetraLogic. "This is an opportunity to build on pioneering basic research to attack infectious disease with a completely novel therapeutic approach."

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

Read more: http://ir.tetralogicpharma.com/releasedetail.cfm?ReleaseID=820211

Comments are closed.

    Archives

    October 2023
    September 2023
    September 2022
    August 2022
    June 2022
    May 2022
    February 2022
    January 2022
    December 2021
    May 2021
    April 2021
    February 2021
    January 2021
    December 2020
    November 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    December 2019
    November 2019
    October 2019
    August 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    April 2015
    March 2015
    February 2015
    January 2015
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    February 2014
    January 2014
    December 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    RSS Feed

© The Vertical Group - [email protected]
 PO 218, Berkeley Heights, NJ 07922 | (908) 277-3737
PO 5006, San Mateo, CA  94402 | (650) 566-9060
Picture
Website by Custom Dynamics